Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Gross Profit (2019 - 2025)

Karyopharm Therapeutics' Gross Profit history spans 6 years, with the latest figure at $32.5 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 10.34% year-over-year to $32.5 million; the TTM value through Dec 2025 reached $140.1 million, changed 0.35%, while the annual FY2025 figure was $140.1 million, 0.47% changed from the prior year.
  • Gross Profit reached $32.5 million in Q4 2025 per KPTI's latest filing, down from $42.0 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $125.5 million in Q4 2021 to a low of $21.5 million in Q2 2021.
  • Average Gross Profit over 5 years is $39.9 million, with a median of $36.4 million recorded in 2023.
  • The largest YoY upside for Gross Profit was 80.5% in 2022 against a maximum downside of 74.74% in 2022.
  • A 5-year view of Gross Profit shows it stood at $125.5 million in 2021, then plummeted by 74.74% to $31.7 million in 2022, then grew by 2.9% to $32.6 million in 2023, then dropped by 9.79% to $29.4 million in 2024, then rose by 10.34% to $32.5 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Gross Profit are $32.5 million (Q4 2025), $42.0 million (Q3 2025), and $36.9 million (Q2 2025).